Lisanne C. de Vos

Learn More
P atients with peripheral artery disease (PAD) are inflicted with a large burden of atherosclerosis, associated with a substantially increased risk for cardiovascular events and premature mortality. Advanced glycation end products (AGEs) are formed by nonenzymatic glycation and oxidative reactions to form stable structures accumulating on long-lived(More)
OBJECTIVE Advanced glycation end products play a pivotal role in atherosclerosis. Recently, we showed that tissue advanced glycation end products deposition, noninvasively assessed by skin autofluorescence (SAF), is increased in patients with peripheral artery disease. The aim of the present study was to establish whether SAF is associated with all-cause(More)
INTRODUCTION Advanced glycation endproducts (AGEs) may be involved in the development of atherosclerosis, beyond diabetes and renal disease. Skin autofluorescence (AF) is a non-invasive marker for AGEs. We examined whether skin AF is increased in (subclinical) atherosclerosis and associated with the degree of atherosclerosis independent of diabetes and(More)
P atients with peripheral artery disease (PAD) are inflicted with widespread atherosclerosis, which imposes a severely increased risk for cardiovascular events and premature mortality. 1 Earlier studies reported a 5-year all-cause mortality rate of 15% to 30% and a recent study of >2.7 million patients with PAD described an even higher all-cause mortality(More)
  • 1